Insulin treatment (NASH-STZ-HI vs NASH-STZ) impacted regulation of many of the same inflammation- and fibrosis-related pathways affected by hyperglycemia, however, with the majority of pathway-associated genes being downregulated (Fig. 6d). This evidence concerns the gene INS and metabolic dysfunction-associated steatohepatitis.